Controversial medical laboratory services company Theranos could be in the throws a crisis. Late Thursday regulators revealed the company’s high-profile blood tests failed quality control tests almost 30% of the time. The report, which was leaked to The Wall Street Journal, paints a troubling picture of a company tagged with a $9 billion valuation based on an easy and inexpensive finger-prick blood test that was promoted as revolutionary. Latest development could put company’s $9 billion valuation in jeopardy It wasn’t long ago Theranos CEO Elizabeth Holmes was proclaiming that nearly 200 different tests could be carried out with her system…
This content is exclusively for paying members of Hedge Fund Alpha
Insider Strategies and Letters to Shareholders from the Top Hedge Funds and Maximize Your Portfolio Growth with Hedge Fund Alpha
Don’t have an account?
Subscribe now and get 7 days free!
